Moreland Nicole J, Waddington Claire S, Williamson Deborah A, Sriskandan Shiranee, Smeesters Pierre R, Proft Thomas, Steer Andrew C, Walker Mark J, Baker Edward N, Baker Michael G, Lennon Diana, Dunbar Rod, Carapetis Jonathan, Fraser John D
School of Biological Sciences and the Maurice Wilkins Centre, University of Auckland, Auckland, New Zealand.
Telethon Institute for Child Health Research, University of Western Australia, Perth, Australia.
Vaccine. 2014 Jun 24;32(30):3713-20. doi: 10.1016/j.vaccine.2014.05.017. Epub 2014 May 14.
Group A Streptococcus (GAS) infections represent a major public health burden in both developing and developed countries. In Australia and New Zealand GAS associated diseases are serious problems in Indigenous populations and a major cause of health inequality. Political recognition of these inequalities is providing impetus for strategies that reduce GAS disease and the development of a GAS vaccine now has governmental support in both Australia and New Zealand. Accordingly, an expert workshop was convened in March 2013 to consider available data on GAS vaccines. M-protein based vaccines constructed from the hyper-variable N-terminal region (30-valent vaccine) or the conserved C-repeat domain (J8 vaccine) were reviewed together with vaccine candidates identified using multi high-throughput approaches. Performing a comprehensive assessment of regional GAS strain epidemiology, defining the immune correlates of protection, and the establishment of clinical trial sites were identified as critical activities for a Trans-Tasman vaccine development programme.
A群链球菌（GAS）感染在发展中国家和发达国家都是一项重大的公共卫生负担。在澳大利亚和新西兰，GAS相关疾病在原住民中是严重问题，也是健康不平等的主要原因。对这些不平等现象的政治认可正在推动减少GAS疾病的策略，并且目前在澳大利亚和新西兰，GAS疫苗的研发均得到政府支持。因此，2013年3月召开了一次专家研讨会，以审议GAS疫苗的现有数据。对基于M蛋白的疫苗（由高变N端区域构建的30价疫苗或保守C重复结构域构建的J8疫苗）以及使用多种高通量方法鉴定的候选疫苗进行了审查。对区域GAS菌株流行病学进行全面评估、确定保护的免疫相关因素以及建立临床试验地点被确定为跨塔斯曼疫苗开发计划的关键活动。
